

10-13-2023

Bilateral Interstitial Keratitis Following COVID-19: A Case Report

Nathalie D. Daher

Zeba A. Syed

Follow this and additional works at: <https://jdc.jefferson.edu/willsfp>



Part of the [Ophthalmology Commons](#), and the [Viruses Commons](#)

[Let us know how access to this document benefits you](#)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Wills Eye Hospital Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

CASE REPORT

Open Access



Bilateral interstitial keratitis following COVID-19: a case report

Nathalie Dalloul Daher¹ and Zeba A. Syed^{1*}

Abstract

Background Although the primary target of severe acute respiratory syndrome coronavirus 2 is the respiratory tract, the expression of the angiotensin-converting enzyme 2 receptor in other tissues facilitates viral entry in others parts of the body, including ocular structures. Ocular manifestations may occur before, during, or after systemic infection.

Case presentation We report the case of a 60-year-old male who presented with bilateral interstitial keratitis after the onset of COVID-19, with ocular symptoms starting within 7 days after systemic symptoms. Laboratory investigation did not identify any alternative etiology for his disease, although the possibility of Epstein-Barr virus or herpes simplex virus could not be definitively ruled out. The patient had already developed significant corneal scarring and visual debilitation by the time topical steroids were initiated, and his final corrected visual acuity with rigid gas permeable contact lenses was 20/50 and 20/80 in the right and left eye, respectively.

Conclusions The involvement of ocular tissue by the virus can lead to permanent sequelae such as severe visual loss, and clinicians should be aware of and recognize ophthalmic manifestations of this disease to prompt early intervention.

Keywords Interstitial keratitis, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19

Background

Since initial reports of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 [1, 2], COVID-19 has affected millions in a worldwide pandemic [1]. This virus uses the angiotensin-converting enzyme 2 (ACE2) receptor to enter host cells in various organs, including ocular structures [3].

Different forms of ocular involvement have been reported including conjunctivitis [1], episcleritis [4], and acute corneal graft rejection [5]. Ocular manifestations may occur before, during, or after systemic infection, and there is no evidence that ocular involvement is related to

the severity of the systemic disease [6]. Direct inoculation of the virus in the conjunctiva, transmission via the nasolacrimal duct, and dissemination through conjunctival vessels are mechanisms through which SARS-CoV-2 can infect the ocular surface [7]. We present a rare case of bilateral interstitial keratitis (IK) in a 60-year-old man shortly after the onset of COVID-19 systemic disease. Bilateral IK related to COVID-19 has been previously reported [8]; the mechanism may involve inflammation secondary to SARS-CoV-2 particles, or reactivation or coinfection by other pathogens including Epstein-Barr virus or herpes simplex virus.

Case presentation

A 60-year-old man was referred for evaluation of bilateral blurry vision, worse in the left eye. He reported no medical history and was not on any systemic medications. Ocular history was notable for allergic conjunctivitis and bilateral primary open-angle glaucoma, and intraocular

*Correspondence:

Zeba A. Syed
zsyed@willseye.org

¹ Cornea Service, Wills Eye Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, 840 Walnut Street, Suite 920, Philadelphia, PA 19107, USA



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

pressures were successfully controlled with dorzolamide-timolol 22.3/6.8 mg/mL twice daily in both eyes and bimatoprost 0.01% nightly in both eyes. He occasionally used preservative-free artificial tears when allergy symptoms flared. The patient had documented normal corneal evaluations prior to symptom onset.

The patient was diagnosed with COVID-19 three months prior to presentation, confirmed by polymerase chain reaction (PCR) testing of a nasal swab specimen. Systemic symptoms lasted for approximately 7 days and included sore throat, chills, and nasal congestion. The patient experienced mild redness, pain, photophobia, and decreased vision in both eyes, left worse than right, towards the end of his systemic syndrome. He attributed his ocular symptoms to allergies and did not seek medical attention. However, his ocular symptoms significantly worsened after his systemic symptoms resolved. One month later, the patient was evaluated by his primary ophthalmologist and found to have bilateral interstitial keratitis. He was treated for presumed herpetic infection with oral valacyclovir 1 g three times daily for 10 days and topical prednisolone acetate 1% four times daily in both eyes. Symptoms improved over the ensuing 2 weeks, however, because bilateral visual acuity remained compromised, the patient was referred to our institution for corneal evaluation.

At presentation, the patient reported his only symptom to be bilaterally reduced vision, worse in his left eye. His best spectacle-corrected visual acuity was 20/80 in the right eye and 20/300 in the left eye. Intraocular pressures were 13 mmHg and 12 mmHg in the right and left eyes, respectively. No relative afferent pupillary defect was noted. Slit lamp evaluation demonstrated that his conjunctiva was white and quiet bilaterally. Examination of the right cornea revealed superficial and deep scarring with stromal vascularization inferotemporally extending approximately 2.5 mm from the limbus. The left cornea had a more advanced clinical picture, with inferonasal superficial and deep scarring and associated vascularization extending approximately 5.5 mm from the limbus into the visual axis (Fig. 1). The anterior chambers were deep and with no inflammation bilaterally. There was mild symmetric nuclear sclerosis that was consistent with the patient's age. Posterior segment examinations were unremarkable. Given the presence of significant corneal scarring, a rigid gas permeable contact lens over refraction was performed, which improved the visual acuity to 20/50 in the right eye and 20/80 in the left eye. The depth of corneal scarring was verified by anterior segment optical coherence tomography (Optovue Inc., Fremont, CA, USA) (Fig. 2).

The clinical picture of bilateral IK prompted laboratory investigation. Laboratory results were positive for




Fig. 1 External photography of the right (A) and left (B) eye

Epstein-Barr virus viral capsid antigen IgG antibody, Epstein-Barr virus nuclear antigen IgG antibody, and herpes simplex virus 1 IgG antibody (Table 1). The remainder of the laboratory testing was negative, including evaluation for syphilis, Lyme disease, and tuberculosis.

The patient was monitored on topical prednisolone acetate 1% four times daily in both eyes, and no improvement in vision or corneal opacification was noted over the ensuing 3 months. Topical steroids were subsequently tapered. Given his functional vision using rigid gas permeable contact lenses, the patient has opted to continue this management course and thus keratoplasty is not planned for the foreseeable future.

Discussion and conclusions

The pathophysiology of COVID-19 involves systemic immune responses, with massive production of inflammatory mediators [2, 3]. The coronavirus enters host cells by binding its spike (S) protein to host ACE2 receptors, and the transmembrane serine protease 2 (TMPRSS2) facilitates viral fusion with the human cell [2, 3, 9]. Although the ACE2 receptor and TMPRSS2 are particularly expressed in type 2 alveolar epithelial cells, they have also been identified in several other tissues such as the conjunctiva, limbus, and cornea [2, 3].



Fig. 2 Anterior segment optical coherence tomography of the right (A) and left (B) corneas demonstrate deep stromal opacification

The human body's immune reaction to SARS-CoV-2 infection involves innate and adaptive responses [9]. An intracellular cascade signal leads to the production of numerous proinflammatory cytokines such as tumour necrosis factor (TNF), interleukin 1 (IL-1) and 6 (IL-6), and interferons (IFNs) [2, 9]. IFNs typically protect the host from viral replication by inducing apoptosis of infected cells, although this cytokine can be suppressed by SARS-CoV-2 proteins [9]. In the reported patient's case, an intense immunological response caused by viral particles may have led to severe injury to the corneal stroma, resulting in IK. This mechanism would be akin to that of stromal keratitis secondary to the herpes simplex virus, in which case herpes virus replication in the cornea triggers an immune signaling cascade and production of cytokines [10]. The resulting influx of inflammatory cells and antigen presenting cells result in both acute and chronic corneal inflammation and vascularization [10].

Approximately 11% of COVID-19 patients have ocular findings [1]. The most common ocular feature of this disease is viral conjunctivitis [1], and other anterior segment manifestations of COVID-19 include keratoconjunctivitis [11], episcleritis [4], and acute corneal graft rejection [5]. Additional ophthalmic manifestations include acute dacryoadenitis [12], cotton wool spots and retinal microhemorrhages [13], posterior scleritis [14], oculomotor nerve palsy [15], optic neuritis [16], Guillan-Barre syndrome [17], Miller Fisher syndrome [18], ophthalmic

artery occlusion [19], and retinal vein occlusion [20]. As ophthalmic findings may precede systemic disease, knowledge of the ocular manifestations of COVID-19 is vital to permit early diagnosis and treatment.

IK involves chronic and nonulcerative inflammation of the corneal stroma with variable neovascularization, usually without epithelial or endothelial involvement [21]. The pathogenesis typically involves an immune-mediated response to foreign antigens, which are usually bacterial, viral, or parasitic [21]. At one institution in the United States, the most common identified causes of IK were herpes simplex virus and syphilis [22]. However, the vast majority of bilateral cases were either idiopathic or secondary to syphilis [22]. Other etiologies include Lyme disease, tuberculosis, Epstein-Barr virus, and acanthamoeba [21]. In our case, the possibility of keratitis due to Epstein-Barr virus or herpes simplex virus could not be definitively ruled out. Patients with severe COVID-19 infection have impaired immunity characterized by a reduction in the number of CD4+ and CD8+ T cells; reactivation or coinfection with other viruses have been well-documented among COVID-19 patients [23]. Although written clinical records of our patient revealed no prior corneal findings prior to COVID-19, we did not have photographic documentation of healthy corneas.

The management of IK typically involves topical inflammatory therapy and treatment of the underlying etiology, when identified [24]. In our case, the patient

Table 1 Laboratory results

Laboratory Test	Result (Reference Interval)
White blood cells	$8.7 \times 10^3/\mu\text{L}$ (3.4–10.8)
Red blood cells	$4.63 \times 10^6/\mu\text{L}$ (4.14–5.80)
Hemoglobin	14.3 g/dL (13.0–17.7)
Hematocrit	41.9% (37.5–51.0)
Platelets	$297 \times 10^3/\mu\text{L}$ (150–450)
Neutrophils (absolute)	$5.4 \times 10^3/\mu\text{L}$ (1.4–7.0)
Lymphocytes (absolute)	$2.6 \times 10^3/\mu\text{L}$ (0.7–3.1)
Monocytes (absolute)	$0.5 \times 10^3/\mu\text{L}$ (0.1–0.9)
Eosinophils (absolute)	$0.1 \times 10^3/\mu\text{L}$ (0.0–0.4)
Basophils (absolute)	$0.1 \times 10^3/\mu\text{L}$ (0.0–0.2)
<i>Immune and Infectious Markers</i>	
Angiotensin-converting enzyme	52 U/L (14–82)
Antinuclear Ab	Negative
EBV VCA, IgM Ab	< 36.0 U/ml (0.0–35.9)
EBV VCA, IgG Ab	158.0 ↑ U/ml (0.0–17.9)
EBV NA, IgG Ab	> 600.0 ↑ U/ml (0.0–17.9)
HSV 1, IgG Ab	1.3 ↑ index (0.0–0.9)
HSV 2, IgG Ab	< 0.91 index (0.0–0.9)
HSV, IgM Ab	< 0.91 ratio (0.0–0.9)
Lyme total Ab	Negative
QuantiFERON-TB Gold Plus	Negative
Rapid plasma reagin	Non-reactive
Sedimentation rate	7 mm/hr (0–30)
Treponema pallidum Ab	Non-reactive
Varicella zoster, IgM Ab	< 0.91 index (0.0–0.9)
Varicella zoster, IgG Ab	2117 index (immune > 165)

Ab Antibody, EBV Epstein-Barr virus, HSV Herpes simplex virus, NA Nuclear antigen, TB Tuberculosis, VCA Viral capsid antigen

was able to achieve functional vision with rigid gas permeable contact lenses. In conclusion, we present a rare case of bilateral IK after the onset of COVID-19 resulting in corneal scarring and decreased vision. We hope that this case highlights the importance of ocular evaluation in patients with COVID-19, as early management of IK may reduce ocular morbidity.

Abbreviations

SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
ACE2	Angiotensin-converting enzyme 2
IK	Interstitial keratitis
PCR	Polymerase chain reaction
S	Spike protein
TMPRSS2	Transmembrane serine protease 2
TNF	Tumour necrosis factor
IL-1	Interleukin 1 and IL-6
IFNs	Interferons

Acknowledgements

Not applicable.

Authors' contributions

NDD contributed to the conception, design, acquisition and interpretation of data, and drafted the work; ZAS contributed to the conception of the study as well as drafting of the manuscript and substantial revision. Both authors read and approved the final submitted manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent form is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare no competing interests.

Received: 19 March 2023 Accepted: 2 October 2023

Published online: 13 October 2023

References

- Nasiri N, Sharifi H, Bazrafshan A, Noori A, Karamouzian M, Sharifi A. Ocular manifestations of COVID-19: a systematic review and meta-analysis. *J Ophthalmic Vis Res.* 2021;16(1):103–12.
- Collin J, Queen R, Zerti D, Dorgau B, Georgiou M, Djidrovski I, et al. Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface. *Ocul Surf.* 2021;19:190–200.
- Zhou L, Xu Z, Castiglione GM, Soiberman US, Eberhart CG, Duh EJ. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. *Ocul Surf.* 2020;18(4):537–44.
- Méndez Mangana C, Barraquer Kargacin A, Barraquer RI. Episcleritis as an ocular manifestation in a patient with COVID-19. *Acta Ophthalmol.* 2020;98(8):e1056–7.
- Jin SX, Juthani VV. Acute corneal endothelial graft rejection with coinciding COVID-19 infection. *Cornea.* 2021;40(1):123–4.
- La Distia NR, Putera I, Khalisha DF, Septiana I, Ridwan AS, Sitompul R. Are eyes the windows to COVID-19? Systematic review and meta-analysis. *BMJ Open Ophthalmol.* 2020;5(1):e000563.
- Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. *Clin Exp Optom.* 2020;103(4):418–24.
- Cano-Ortiz A, Leiva-Gea I, Ventosa Á, González-Cruces T, Sánchez-González JM, Morales P, et al. Stromal interstitial keratitis in a patient with COVID-19. *J Fr Ophtalmol.* 2022;45(4):e175–7.
- Van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, et al. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. *J Pathol.* 2021;254(4):307–31.
- Lobo AM, Agelidis AM, Shukla D. Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation. *Ocul Surf.* 2019;17(1):40–9.
- Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). *Can J Ophthalmol.* 2020;55(4):e125–9.
- Martínez Díaz M, Copete Piqueras S, Blanco Marchite C, Vahdani K. Acute dacryoadenitis in a patient with SARS-CoV-2 infection. *Orbit.* 2022;41(3):374–7.
- Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R. Retinal findings in patients with COVID-19. *Lancet.* 2020;395(10237):1610.

14. Collange O, Tacquard C, Delabranche X, Leonard-Lorant I, Ohana M, Onea M, et al. Coronavirus Disease 2019: Associated Multiple Organ Damage. *Open Forum Infect Dis.* 2020;7(7):249.
15. Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. Author response: COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. *Neurology.* 2020;95(9):411.
16. Tisdale AK, Chwalisz BK. Neuro-ophthalmic manifestations of coronavirus disease 19. *Curr Opin Ophthalmol.* 2020;31(6):489–94.
17. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med.* 2020;382(26):2574–6.
18. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. *Neurology.* 2020;95(5):e601–5.
19. Dumitrascu OM, Volod O, Bose S, Wang Y, Biousse V, Lyden PD. Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. *J Stroke Cerebrovasc Dis.* 2020;29(8):104982.
20. Sheth JU, Narayanan R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: a novel entity. *Indian J Ophthalmol.* 2020;68(10):2291–3.
21. Gauthier AS, Noureddine S, Delbosc B. Interstitial keratitis diagnosis and treatment. *J Fr Ophtalmol.* 2019;42(6):e229–37.
22. Schwartz GS, Harrison AR, Holland EJ. Etiology of immune stromal (interstitial) keratitis. *Cornea.* 1998;17(3):278–81.
23. Kim JYH, Ragusa M, Tortosa F, Torres A, Gresh L, Méndez-Rico JA, et al. Viral reactivations and co-infections in COVID-19 patients: a systematic review. *BMC Infect Dis.* 2023;23(1):259.
24. Martin J, Kopplin L, Costakos D. Syphilitic interstitial keratitis treated with topical tacrolimus. *Am J Ophthalmol Case Rep.* 2021;23:101175.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

